EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 654 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults June 15, 2023 OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally... August 4, 2025 TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness... August 23, 2022 Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... July 19, 2022 Load more HOT NEWS Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival... New Year’s Wishes 2016 10 Ways to Brave Cancer Treatment: Tips from a Survivor Conducting Phase I Clinical Trials During the COVID-19 Pandemic
